Tuesday - July 24, 2018Health Yourself – why you should care about self-careWe’ve seen significant advances in modern medicine, however, consistent with our growing and ageing population and our modern lifestyles, chronic disease is on the rise. Find out what you can do to look after yourself. More
Monday - June 11, 2018Phosphorus just the tonic for needy cowsStrong demand from vets and farmers // Highest amount of phosphorus available for nutritional supplementation More
Thursday - May 31, 2018Treatment to tackle the country’s two leading causes of blindness now funded on the Pharmaceutical ScheduleEYLEA® (aflibercept) is available under PHARMAC funding from 1 June for the treatment of Wet Age Related Macular Degeneration (wet-AMD) and Diabetic Macular Oedema (DMO) More
Friday - May 25, 2018Bayer is making good progress strategicallyAcquisition of Monsanto expected to be closed in the near future / 2017 sales and earnings at the prior-year level / Dividend to be raised for the eighth time in succession – to 2.80 euros per share / Start to fiscal 2018 overshadowed by currency effects More
Thursday - May 03, 2018Bayer Q1 2018: Operational business held back by currency effects – Major progress with Monsanto acquisitionGroup sales increase by 2.0 percent (Fx & portfolio adj.) to 9.138 billion euros / EBITDA before special items down year on year due to currency effects / Net income declines by 6.2 percent to 1.954 billion euros / Core earnings per share down 1.3 percent at 2.28 euros / European Commission and additional regulators conditionally approve Monsanto acquisition / Currency adjusted Group outlook for 2018 confirmed More
Wednesday - March 21, 2018European Commission conditionally approves Bayer’s proposed acquisition of MonsantoClosing of transaction planned for the second quarter of 2018 More
Wednesday - February 28, 2018Bayer: business at prior-year level – on track with strategyGroup sales increased by 1.5 percent (Fx & portfolio adj.) to 35.015 billion euros / Another record year for Pharmaceuticals / Weak business development at Consumer Health / Crop Science business down against prior year due to situation in Brazil – measures taking effect / EBITDA before special items level year on year at 9.288 billion euros / Net income raised by 61.9 percent to 7.336 billion euros / Core earnings per share increased by 1.0 percent to 6.74 euros / Covestro deconsolidated – additional cash inflows of 4.7 billion euros / Monsanto acquisition expected to close in second quarter of 2018 / Group outlook for 2018: increase in sales (Fx & portfolio adj.), EBITDA before special items and core earnings per share at prior-year level due to currency effects More
Monday - December 04, 2017Partnership a boost for rural health and wellbeingFocus on rural youth health and suicide prevention // Collaboration key to success // $80,000 initial investment More
Wednesday - November 15, 2017Heiko Schipper to join Bayer Board of Management and head Consumer Health DivisionErica Mann to leave Bayer effective March 31, 2018 More
